The FDA's Peptide Vote Is In: What the PCAC Actually Decided on BPC-157, TB-500, and More

For months, this site has covered the FDA''s peptide compounding fight as an upcoming event. It''s no longer upcoming — the Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026, and the actual votes are in. Here''s what really happened, and an honest look at what it does and doesn''t change. A Quick Recap of How We Got Here Section 503A of federal drug law lets compounding pharmacies prepare individualized prescriptions using bulk substances on an approved "Bulks List" — Category 1 means compounding is permitted, Category 2 means it's prohibited. Between September 2023 and December 2024, roughly 19 widely-used compounded peptides, including BPC-157 and TB-500, were moved into Category 2, cutting off the legal compounding pathway. In February 2026, HHS signaled a policy reversal, and on April 15, 2026, FDA formally removed 11 of those peptides from Category 2 as a procedural first step, while scheduling the PCAC to formally evaluate seven of them this July. The Actual Vote: 6 of 7 Recommended, All by Narrow Margins The committee reviewed seven peptide substances (each in both free base and acetate form) over two days at FDA's White Oak campus. The results: BPC-157 — recommended, 8 yes, 6 no, 1 abstention (nominated for ulcerative colitis) KPV — recommended, similarly narrow margin (nominated for wound healing and inflammatory conditions) TB-500 — recommended, 8-6 with one abstention (nominated for wound healing) MOTS-c — recommended, 7 yes, 5 no, 2 abstentions (nominated for obesity and osteoporosis) Semax — recommended on day two (nominated for cerebral ischemia, migraine, trigeminal neuralgia) Epitalon — recommended on day two (nominated for insomnia) Emideltide (DSIP) — the only rejection, voted down 7-6 with one abstention (nominated for opioid withdrawal, chronic insomnia, narcolepsy) Every single recommendation passed by a margin of one or two votes — genuinely narrow outcomes, not a confident consensus in either direction. The Part Most Headlines Undersold: This Overrode FDA's Own Scientists This is the detail worth sitting with. FDA's own career reviewers, in briefing documents prepared ahead of the meeting, had recommended against adding any of the seven substances — citing that available studies, including five trials specifically on BPC-157, were short in duration, small in sample size, and insufficient to establish safety or effectiveness for the indications under review. The committee voted to recommend six of the seven anyway, directly against its own agency's scientific staff recommendation. Also worth knowing: the reconstituted PCAC roster for this meeting drew real scrutiny for including more health professionals who prescribe, produce, or promote peptides commercially than prior iterations of the committee, a shift from panels historically composed mainly of academic researchers. That's a legitimate conflict-of-interest concern raised by outside observers covering the meeting, not a settled judgment — but it's relevant context for how much weight to put on the committee's recommendation itself. What This Actually Changes Right Now: Less Than You'd Think This is the most important part for anyone trying to figure out what this means practically. The PCAC's vote is a non-binding recommendation. FDA is not required to follow it in either direction. The realistic next steps, per FDA's own standard process: the agency reviews public docket comments and its own further analysis, then publishes a proposed rule describing which substances it actually intends to add to the Bulks List, opens another public comment period, and only then issues a final rule. That full process, under standard timelines, typically takes more than a year from a favorable recommendation to final legal authorization. Confirming this isn't just theoretical caution: as of late July 2026, the formal legal compounding list itself (21 CFR 216.23) still does not include any of these six peptides. The substances that list currently covers are unrelated topical compounds (things like cantharidin and thymol iodide) — none of the six peptides voted on this month have been added. Removal from Category 2 back in April was a procedural change enabling further evaluation, not an authorization to compound, and the July vote doesn't change that fact either. What This Means for RUO Access and Pricing, Revisited Everything covered in our original analysis of this situation still holds, now with more certainty rather than less: the RUO/gray-market channel remains the default access route for these compounds, and will keep being the default for the realistic near-term — likely into 2027 at the earliest, even under the more favorable outcome that actually occurred this month. A positive PCAC recommendation is a meaningful directional signal, but it is not the green light some coverage implied. Pricing and quality-control dynamics in the gray market aren't going to shift meaningfully until an actual final rule exists, and that's still, by FDA's own standard timeline, over a year away at best. What's Still Ahead The second PCAC meeting, covering five additional substances (GHK-Cu, Melanotan II, Cathelicidin/LL-37, Dihexa acetate, and PEG-MGF), remains scheduled for before the end of February 2027 and has not yet occurred. The Bottom Line The vote happened, and it went further than FDA's own scientists recommended — six of seven peptides got a narrow, non-binding thumbs-up from the advisory committee, overriding staff concerns about thin safety and efficacy data. But "recommended by an advisory committee" and "legally compoundable" remain two very different things, separated by a rulemaking process that's still measured in months to years, not days. If you're navigating this space as a consumer or a business, the honest read is: watch for the actual proposed rule, not the committee vote, as the signal that meaningfully changes anything on the ground.